In Situ Hybridization Market Growth Drivers, Vendor Landscape and Raw Material Outlook

In Situ Hybridization Industry Overview

The global in situ hybridization market size is expected to reach USD 2.6 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.9% from 2021 to 2028. The growing popularity of in-vitro diagnostics over conventional disease diagnostic methods has majorly driven the ISH market over the past years.

The market is gaining momentum in breast cancer with the FISH test. For instance, Roche offers a comprehensive ISH workflow solution with automated assay and digital pathology for breast cancer. Thus, increasing the scope of application is expected to drive the market to a major extend. In addition, technological advancements in instruments have fueled the market growth.

In Situ Hybridization Market Segmentation

Grand View Research has segmented the global in situ hybridization market based on technology type, probe, product, application, end-use, and region:

Based on Technology Insights, the market is segmented into Fluorescent In Situ Hybridization (FISH), and Chromogenic In Situ Hybridization (CISH).

• FISH segment dominated the market for in situ hybridization and accounted for the largest revenue share of 53.9% in 2020. This can be attributed to the wide range of applications such as diagnosing congenital diseases including Edward's Syndrome and Down's Syndrome.
• The CISH segment also captured a significant share of in situ hybridization over time as it is a cost-effective, reliable, and practical alternative for FISH.

Based on the Probe Type Insights, the market is segmented into DNA and RNA.

• The DNA probe segment dominated the market for in situ hybridization and accounted for the largest revenue share of 51.1% in 2020.
• However, the RNA probe showcased a better growth rate in the forecasted period, owing to the development of new nucleic acid-based diagnostic assays and tools for analyzing DNA and RNA molecules.

Based on the Application Insights, the market is segmented into Cancer, Cytogenetics, Developmental Biology, Infectious Diseases, and Others

• The cancer segment dominated the market for in situ hybridization and accounted for the largest revenue share of 36.4% in 2020.
• The increase in the incidence rate of cancer cases is anticipated to drive the growth.

Based on Product Insights, the market is segmented into Instruments, Kits and Probes, Software, and Services.

• The instruments segment dominated the market for in situ hybridization and accounted for the largest revenue share of 36.3% in 2020.
• On the other hand, the services segment is anticipated to witness significant growth in the market for in situ hybridization.

Based on the End-use Insights, the market is segmented into Hospitals & Diagnostic Laboratories, Contract Research Organizations (CROs), Academic & Research Institutions, and Others

• The hospitals and diagnostic laboratories segment dominated the market for in situ hybridization and accounted for the largest revenue share of 48.8% in 2020.
• The ongoing pandemic can be the key driver for the laboratories as understanding the pathogen can offer a competitive advantage to the laboratories and assist to lead the industry.
• Likewise, the Contract Research Organizations segment is growing at a faster pace, although the absolute value of revenue is less compared to the other segments.

In Situ Hybridization Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

Key Companies Profile & Market Share Insights

The in-situ hybridization market is competitive in nature and some of the key players accounted for the largest market share owing to their extensive product portfolios and geographic presence across the world.

Some prominent players in the global In Situ Hybridization market include:

• Thermo Fisher Scientific
• Leica Biosystems Nussloch GmbH
• BIO VIEW
• Agilent Technologies
• Merck KGaA
• PerkinElmer, Inc.
• Bio-Rad Laboratories, Inc.
• NeoGenomics Laboratories, Inc.
• Advanced Cell Diagnostics, Inc.
• Oxford Gene Technology

Order a free sample PDF of the In Situ Hybridization Market Intelligence Study, published by Grand View Research.

In Situ Hybridization Market Top Companies Analysis, Global Demand, and In-depth Research Report, 2024

The Global In Situ Hybridization Market is subject to witness a substantial growth due to the rising demand for molecular diagnostic tools and increasing adoption of ISH technology. Growing prevalence of chronic diseases along with rising demand for rapid diagnostic techniques are anticipated to foster market growth over the forecast period. Globally, the market is predicted to grow at CAGR of 7.8% in the forecast period, providing numerous opportunities for market players to invest for research and development in the In Situ hybridization market.

The conventional methodologies such as clinical trials were influenced by factors such as the growing competition, rising prices of medicines and strict governmental laws to limit adverse effects on the environment. With advent of the In Situ hybridization, such factors are significantly diminished due numerous advantages provided with the use of the In Situ hybridization. Benefits associated with adoption of In Situ hybridization are superior performance, successful trials, reliability and short timeframes for execution of clinical trial, and cost-effectiveness.

Rising prevalence of cancer-related diseases is expected to boost market demand for In Situ hybridization over the upcoming years. In addition, increasing adoption of DNA probe-based diagnostics for identification of diseases that are caused by pathogen or bacteria is estimated to drive market growth. Rise in the number of incidence related to genetic disorders, solid tumors, leukemia, autism, and other syndromes are predicted to stimulate market demand for In Situ hybridization over the forecast period.

The market is broadly categorized into major four segments based on the product type such as instruments, kits & probes, software and services. The instruments is considered as one of the fastest growing segment in the In Situ hybridization market with substantial revenue generation in the last few years. Growing popularity of the instruments segment among healthcare professionals is attributed to the rise in the demand from diagnostic and research laboratories. The kits & probes segment has also witnessed substantial growth owing to the growing incidence of target disorders such as cancer.

Get Free Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/in-situ-hybridization-ish-market-share/request-sample

The market is divided by region as North America, Europe, Asia-Pacific, Latin America and Africa. North America has shown major growth in recent years owing to the rise in the implementation of latest technologies in pharmaceuticals & medicine sector, higher penetration rates, increase in the demand for disposable devices from healthcare professionals, and existence of well-established infrastructure.

Asia-Pacific region is predicted to hold major market share in the In Situ hybridization market with massive growth in forecast period. Countries such as India, China and Singapore are leading the Asia-Pacific market with increasing healthcare expenditure, growing prevalence of cancer related diseases, presence of high-unmet patient needs, and significant investment by leading industry players considering potential growth opportunities in the region.

The key players in the In Situ hybridization market are Thermo Fisher Scientific Co., Leica BiosystemsNussloch GmbH, BIOVIEW, Inc., Agilent Technologies, Inc., Merck KGaA, PerkinElmer, Inc., Bio-Rad Laboratories, Inc., NeoGenomics Laboratories, Inc., Advanced Cell Diagnostics, Inc., and Oxford Gene Technology Co.

Browse Related Category Reports @ https://industriesstudyreport.blogspot.com/